Research & Development
Propanc Biopharma signs research agreement for the POP1 drug discovery programme with the University of Jaén, Spain
20 September 2018 -

Biopharmaceutical company Propanc Biopharma Inc (OTCQB:PPCB) said on Wednesday that it plans to provide cancer research services and scientific technical advice for the POP1 drug discovery programme under a research collaboration agreement with the University of Jaén, Spain.

Through the POP1 drug discovery programme, the company plans to synthesize and develop a backup clinical compound to its lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumours. Progressing towards a first-in-human study, PRP seeks to prevent recurrence and metastasis from solid tumours by targeting and eradicating cancer stem cells.

Under the collaboration,the parties will be engaged in the identification a suitable backup clinical compound to PRP, the validation of the anti-carcinogenic properties of the new drug candidate through in vitro testing, the validation of the anti-carcinogenic properties of the new drug candidate through in vivo testing as well as the production of the new synthetic drug candidate in compliance with US FDA's "current good manufacturing practice" (cGMP) conditions, to be used in human trials.

In conjunction with the partnership, Dr Macarena Perán Quesada, Professor at the University of Jaén, will be in charge of management and coordination of the working team and will be the scientific consultant in charge of the project run by the University of Jaén.

Dr Perán is the lead author of several scientific papers jointly published with the company regarding the anti-cancer and anti-tumour effects of PRP, as well as a co-inventor of several patents in the Company's intellectual property portfolio, including the discovery of PRP as a targeted, cancer stem cell therapy.

Login
Username:

Password:


Related Headlines